SHP-1, a haematopoietic cell-specific tyrosine phosphatase, is also expressed in human prostate. In this study, we report that SHP-1 depletion in PC-3 cells induced by small interfering RNAs causes G1 phase cell-cycle arrest accompanied by changes in some components of the cellcycle machinery. SHP-1 knockdown increases p27 Kip1 (p27) protein stability, its nuclear localization and p27 gene transcription. These effects could be mediated by PI3K-AKT pathway as SHP-1 interacts with PI3K regulating its activity and p110 catalytic subunit phosphorylation. The increase in p27 protein stability could also because of reduced cyclin-dependent kinase (CDK2) activity. SHP-1 knockdown decreases the CDK6 levels, inducing retinoblastoma protein hypophosphorylation, downregulation of cyclin E and thereby a decrease in the CDK2 activity. However, the codepletion of SHP-1 and p27 does not produce re-entry into the cycle, implying that p27 is not required to maintain cell-cycle arrest induced by SHP-1 depletion. The maintenance of the PC-3 cell antiproliferative response after p27 loss could be because of mislocalization of CDK2 induced by SHP-1 knockdown. This study shows that SHP-1 depletion promotes cellcycle arrest by modulating the activity of cell-cycle regulators and suggests that SHP-1 may be required for the proper functioning of events governing cell-cycle progression.
Introduction
The tyrosine phosphatase SHP-1 is a cytosolic protein containing two N-terminal-located SH2 domains that are expressed at high levels in haematopoietic cells and moderately in many other cell types, including prostate epithelial cells (Valencia et al., 1997; Zapata et al., 2002) .
The essential role of SHP-1 as a negative regulator of signal transduction is consistent with the multiple defects in haematopoietic cells observed in moth eaten mice characterized by the loss of SHP-1 activity Pani et al., 1995 Pani et al., , 1996 Chen et al., 1996) . SHP-1 is also present in normal prostate, benign prostatic hyperplasia, prostatic intraepithelial neoplasia and well-differentiated adenocarcinoma but not in poorly differentiated prostate cancer and seems to be involved in somatostatin-mediated inhibition of human prostate adenocarcinoma cell line PC-3 proliferation (Zapata et al., 2002) . SHP-1 is, thus, generally considered to be a negative regulator of cell proliferation. However, the current understanding of the highly complex function of SHP-1 has matured to encompass a less simplistic view of the influence of this protein on cell signalling pathways, whereby the enzyme, depending on its target molecules and cell type, may function either as a positive or negative mediator. Thus, it has been reported that SHP-1 is positively involved in EGF-and INF-g-induced STAT activation in non-haematopoietic HeLa cells (You and Zhao, 1997) . Furthermore, overexpression of a catalytically inactive mutant of SHP-1 in HEK293 cells strongly suppresses mitogen-activated pathways and reduces cell growth and DNA synthesis (Su et al., 1996) .
Progression through the cycle of cell division is regulated by the coordinated activities of cyclin, cyclin-dependent kinases (CDKs) and CDK inhibitors (Malumbres and Barbacid, 2009 ). CDK4 and CDK6 form complexes with one of several D-type cyclins and function early in the G1 phase. CDK2 complexed with cyclins A and E is essential for the DNA replication and G1/S transition, respectively (Sherr, 1994) .
One of the critical targets of cyclin-CDK complexes is the retinoblastoma gene product (Rb), which acts as a transcriptional repressor. In its hypophosphorylated form, it binds to the E2F family of cell-cycle transcription factors during G1 phase and inhibits E2F activity. Rb is inactivated by CDK phosphorylation in the mid-to late-G1 phase of the cell cycle and dissociates from E2F, leading to the activation of genes containing E2F sites and the progression from G1 to S phase (Harbour and Dean, 2000) .
Another level of regulation of CDK activity arises from the action of CDK inhibitors (Sherr and Roberts, 1999; Besson et al., 2008) . In mammalian cells, the CDK inhibitor p27 binds and inhibits cyclin E/CDK2 and thereby negatively regulates entry into S phase. To traverse G1, cellular p27 levels must decrease. A major mechanism that enables this regulation involves ubiquitin-dependent p27 proteolysis (Pagano et al., 1995; Hengst and Reed, 1996) . Two rate-limiting steps for this process include phosphorylation at Thr 187 by CDK2 and recognition of Thr 187-phospho-p27 by the SCFskp2 ubiquitination system (Sheaff et al., 1997; Slingerland and Pagano, 2000) . Evidence also exists for transcriptional regulation of p27 (Inoue et al., 1999) . Synthesis of p27 mRNA is governed by the Forkhead transcription factor family (Medema et al., 2000) , which is negatively regulated by the phosphatidylinositol 3-kinase/Akt growth signalling pathway.
The involvement of p27 in the negative regulation of cell proliferation has been linked to SHP-1, but contradictory results have been obtained. It has been shown in CHO cells (Pages et al., 1999) that the somatostatin analogue RC160 promotes G1 cell-cycle arrest of insulin-treated cells by a mechanism involving the stimulation of SHP-1 and the consequent upregulation of p27. SHP-1 also mediates the anti-proliferative activity of metalloproteinase-2 tissue inhibitor in human microvascular endothelial cells, increasing de novo synthesis of p27 with a concomitant inhibition of CDK4 and CDK2 activity (Seo et al., 2006) . However, the treatment of human ovarian cancer cells with a PTP inhibitor progressively stopped their ability to form tumours and increases the intracellular levels of CDK2/ p27 and CDK2/SHP-1 complex (Caron et al., 2008) , suggesting that inhibitors of protein tyrosine phosphatase could be used as potential anti-tumour agents. Thus, the role of SHP-1 in the regulation of the cell cycle is far from clear and no studies have yet been performed that clarify the mechanism by which SHP-1 could modulate the levels, location and activity of proteins involved in cell-cycle control.
In this study, we used small interfering RNAs (siRNAs) to knock down the expression of SHP-1 in PC-3 cells and thereby to analyse its relationship with the cell cycle.
Results
Effect of SHP-1 knockdown on PC-3 cell proliferation As knowledge of the intracellular distribution of SHP-1 may provide an insight into their cellular function and regulation we carried out immunofluorescence staining assays to determine the subcellular location of SHP-1 in PC-3 cells. Examination of these cells using confocal microscopy revealed that SHP-1 is present in the nucleus and cytoplasm (Supplementary Figure S1) , suggesting that this phosphatase can control processes in both cellular compartments. To gain insight into the molecular roles of SHP-1, we used siRNAs to knock down the expression of SHP-1 and then analysed the effects on cell proliferation and cell-cycle regulators governing G1/S transition. Western blot analysis shows that the expression of SHP-1 decreased by up to 75% (Figure 1a ). The analysis of the effects of SHP-1 knockdown on PC-3 cell proliferation showed that the depletion of SHP-1 resulted in a significant reduction (22%) in the proliferation rates (Figure 1b ) that was associated with a significant inhibition of DNA synthesis (35%) compared with the control, as measured by the incorporation of thymidine-3 H (Figure 1c ). SHP-1 knockdown-induced growth suppression was associated with cell-cycle arrest. As shown in Figure 1d , the loss of SHP-1 expression led to a 31% increase in the G1-phase fraction and a concomitant decrease in the S-and G2/M-phase fractions. These results show that the decrease in SHP-1 inhibits PC-3 cell proliferation owing to the block of progression from G1 to S phase.
Effect of SHP-1 knockdown on p27 protein levels and subcellular localization To establish whether p27 participates in the antiproliferative effect induced by depletion of SHP-1, we measured p27 protein expression in SHP-1-depleted cells and found a dramatic increase in the p27 levels in SHP-1 knockdown cells compared with that of control siRNA (Figure 2a, top) . A similar result was observed in LNCaP and DU145 human prostate cancer cells (Supplementary Figure S2) , suggesting that p27 upregulation induced by SHP-1 depletion is a general event in human prostate carcinogenesis.
We further analysed the effect of SHP-1 on p27 expression at the transcriptional level. We observed that the knockdown of SHP-1 induced a twofold increase in p27 mRNA (Figure 2a, bottom) . To further explore whether the SHP-1 knockdown-mediated p27 mRNA induction could be caused by activation of the p27 transcriptional promoter, PC-3 cells were transiently transfected with a cDNA vector containing luciferase reporter gene, controlled by promoter regions of human p27 (p27 Luc, from À3568 to À549) or with the empty vector as a control. As shown in Figure 2b , the knockdown of SHP-1 induced a threefold activation of p27 promoter, as measured by luciferase activity, indicating that the regulation of p27 protein levels by SHP-1 could be, at least partially, explained by the regulation of its promoter activity.
To evaluate whether SHP-1 also regulates p27 protein stability, we blocked translation of p27 mRNA with cycloheximide in SHP-1-depleted cells. The half-life of p27 protein increased from B4.5 h in control cells to more than 6 h in SHP-1-silenced cells, clearly indicating that p27 protein was more stable in SHP-1 knockdown cells ( Figure 2c ). As p27 degradation is controlled by Thr 187 phosphorylation we analysed the effect of SHP-1 knockdown on the phosphorylation status of p27-Thr 187. The results shown in Figure 2d show that siRNA-mediated knockdown of SHP-1 causes a dramatic reduction (78%) in p27 phosphorylation on Thr 187, as shown by the decrease in the ratio of Thr 187-phospho-p27 to total p27.
Together these data clearly show that accumulation of p27 protein induced by the loss of SHP-1 is due to the increase in p27 gene transcription and to the decrease in p27 protein degradation arising, at least in part, from the lower level of phosphorylation of Thr 187.
The block of cell cycle mediated by SHP-1 knockdown could be explained not only by the upregulation of p27 protein levels under these conditions but also by changes in its subcellular location. To explore this idea, we first carried out immunofluorescence staining assays to determine cellular location of p27 in PC-3 cells after knockdown of SHP-1. We observed that the depletion of SHP-1 induced an increase in p27 in the nucleus compared with control cells (Figure 3a) . Moreover, when we performed a cell fractionation assay we also found an increase in p27 levels in nuclear compartments (Figure 3b ). p27 phosphorylation at Ser 10 or Thr 157 facilitates the nuclear-to-cytoplasmic redistribution of p27 (Boehm et al., 2002; Liang et al., 2002) . We observed that the increase in nuclear localization of p27 induced by SHP-1 knockdown was associated with a decrease in 55% in p27 Thr 157 phosphorylation, as demonstrated by the decrease in the ratio of Thr 157-phospho-p27 to total p27 ( Figure 3c ). Changes in p27 Ser 10 phosphorylation were not detected ( Figure 3c ).
It is well established that the PI3K-AKT pathway regulates p27 transcription, stability and subcellular localization (Medema et al., 2000; Liang et al., 2002) . In this sense, we have shown that inhibition of PI3K with LY-294002 increases the p27 levels in PC-3 cells (Supplementary Figures S3) . To address the potential role of this pathway in the effects induced by SHP-1 depletion, we analysed the possible functional interaction between SHP-1 and PI3K. As shown in Figure 4a , the p85 regulatory subunit of PI3K coprecipitates with SHP-1. This interaction was confirmed by the pull-down assay ( Figure 4b ). To further examine whether SHP-1 modifies tyrosine phosphorylation of p85 and, thus, PI3K activity, we immunoprecipitated (IP) p85 in SHP-1-depleted cells and analysed the tyrosine phosphorylation profile (Figure 4c ). Interestingly, in SHP-1-depleted cells, the tyrosine phosphorylation of a band with a molecular mass of approximately 110 kDa was increased in comparison with the control cells. This band was proven to be the p110 catalytic subunit of PI3K by immunoblotting the same samples with an anti-p110 antibody. The amount of p110 that coprecipitated with p85 was not modified by SHP-1 knockdown. To determine whether these changes in the tyrosine phosphorylation of p110 are associated with a change in PI3K activity, we measured the AKT Ser473 phosphorylation as a surrogate indicator of this activity (Andjelkovic et al., 1997) . As indicated in Figure 4d , SHP-1 knockdown induced a decrease in the AKT Ser SHP-1 regulates multiple components of cell-cycle machinery FJ Rodríguez-Ubreva et al 473 phosphorylation. These data indicate a role for SHP-1 in regulating not only p110 phosphorylation but also PI3K activation.
Contribution of p27 to cell proliferation inhibition induced by SHP-1 knockdown To test whether the SHP-1 knockdown-induced growth arrest was mediated by upregulation of the p27 protein, we depleted SHP-1 and p27, individually or together, and analysed cell proliferation by thymidine-3 H incorporation assay. As we expected, reduced p27 expression resulted in a slight increase in cell proliferation, whereas SHP-1 knockdown induced a significant decrease in this proliferation. However, the codepletion of p27 and SHP1 did not revert the inhibitory effect caused by SHP-1 removal ( Figure 5 ). This result seems to indicate that p27 is not the only factor involved in the growth arrest induced by the decrease in SHP-1 levels. After 24 h of siRNA transfection, cells were transiently transfected with p27 luciferase reporter construct or with control empty vector, and a Renilla luciferase reporter to normalize transfection efficiency. After 48 h, luciferase activity was determined with a luciferase assay system kit. (c) Seventy-two hours post siRNA transfection, cells were treated with cycloheximide (100 mg/ml) for 3 or 6 h and the cell lysates were immunoblotted with the indicated antibodies. (d) Seventy-two hours post siRNA transfection, SHP-1, p27, phospho-p27 (T187) and b-tubulin protein levels were analysed by western blot. The phosphorylation levels of p27 (T187) were quantified as the ratio of phospho-p27(T187) to p27 expression. ** indicates Po0.01 in comparisons with control cells (Wilcoxon test). Error bars represent the s.e.
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Effect of SHP-1 knockdown on the function of G1/S-related cell-cycle regulators As p27 accumulation is not essential for inhibiting PC-3 cell proliferation induced by SHP-1 knockdown we analysed the effect of SHP-1 siRNA on cell-cycle regulators that act at the G1/S-phase transition. First, we determined the function of cyclin E-CDK2 complex. p27 is both an inhibitor and a substrate of this complex (Besson et al., 2008) . CDK2 kinase activity was measured in CDK2 immunoprecipitates prepared from cells treated with control or SHP-1 siRNA. As shown in Figure 6a , SHP-1 depletion resulted in a significant inhibition of CDK2 activity. The depletion of SHP-1 did not affect the abundance of CDK2 but decreased levels of its partner, cyclin E (Figure 6b ). For CDK2 to be fully activated, newly synthesized CDK2 must translocate into the nucleus (Sebastian et al., 1993; Hoffmann et al., 1994) . To test whether the SHP-1-mediated effects on CDK2 kinase activity might involve regulation of CDK2 localization, control and SHP-1 siRNA-treated PC-3 cells were subjected to immunofluorescence staining of CDK2. Examination of these cells, using confocal microscopy, revealed that knockdown of SHP-1 induces the accumulation of CDK2 in the cytoplasm compared with control cells (Figure 6c ). We also immunofluorescently stained cyclin E and did not observe changes in its localization (data not shown). To understand the mechanism responsible for the CDK2 mislocalization, we next determined whether this kinase interacts with SHP-1. Using glutathione S-transferase (GST)-SHP-1 pull-down assay we found that CDK2 interacts with SHP-1 (Figure 6d ). These results suggest that SHP-1 knockdown reduces CDK2 activity by two mechanisms: one that reduces amounts of cyclin E and another that causes CDK2 mislocalization. Cyclin E is under the control of the E2F family transcriptional factors, which are blocked by hypophosphorylated Rb protein (pRb). The phosphorylation of The extractions of total cell lysates, cytosolic, and nuclear fractions were performed and these fractions were immunoblotted with anti-p27 antibody. b-tubulin was used as a cytosolic fraction loading control and PARP as a nuclear fraction loading control. (c) Total cell lysates were immunoblotted with the antibodies indicated. The phosphorylation levels of p27 (T157) and p27 (S10) were quantified as the ratio of phospho-p27 (T157) to p27 expression or phospho-p27 (S10) to p27 expression, respectively. Representative images of three independent experiments are shown.
SHP-1 regulates multiple components of cell-cycle machinery FJ Rodríguez-Ubreva et al pRb is initially catalysed by the complexes formed by cyclin D and CDK4 or CDK6 (Harbour and Dean, 2000) . As shown in Figure 7a , SHP-1 knockdown induces a reduction of CDK6 levels without causing changes in the cyclin D levels. To determine whether this modification in CDK6 levels affected cyclin D-CDK6 complex activity, we studied the phosphorylation status of pRb and found a decrease in the phosphorylation of pRb at Ser 795, 807 and 811, without changes in the total level of pRb (Figure 7b ). These residues have been identified as being phosphorylated initially by cyclin D-CDK4/6 complexes (Zarkowska and Mittnacht, 1997 ) and thus its lower phosphorylation level implies that the cyclin D-CDK6 complex is less active. These results indicate that SHP-1 knockdown decreases the activity of cyclin D-CDK6 by inducing pRb hypophosphorylation and thereby downregulating cyclin E.
Discussion
In this study, we report, for the first time, that SHP-1 depletion inhibits PC-3 cell proliferation by regulating the levels and activity of components within the machinery that governs the G1/S transition. SHP-1 depletion resulted in a significant accumulation of p27, a decrease in CDK6 levels, pRb hypophosphorylation, a decrease in cyclin E levels associated with a significant inhibition of cyclin E-CDK2 activity and cell-cycle arrest. Taken together, these findings strongly suggest the following sequence of events: the decrease in CDK6 expression observed in SHP-1-depleted cells reduces the formation of the cyclin D-CDK6 complex, resulting in reduced pRb phosphorylation. It is well known that hypophosphorylated pRb can repress the activity of E2F family members by inhibiting, among other 
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FJ Rodríguez-Ubreva et al activities, cyclin E transcription that would be the responsible for the reduced CDK2 activity. We also made the novel observation that SHP-1 depletion decreases the nuclear localization of CDK2, and thus, its full activation, contributing to prevent cyclin E-CDK2 activation. The end result is a decrease in p27 phosphorylation on Thr 187, which increases its stability and accumulation in the cell. Furthermore, SHP-1 knockdown also increases p27 gene transcription and promotes its nuclear localization. The PI3K-AKT pathway is one of the main regulators of p27 levels. Akt is known to phosphorylate p27 at Thr 187 and Thr 157, contributing to its degradation and promoting its cytoplasmic localization, respectively (Fujita et al., 2002; Liang et al., 2002) . Moreover, AKT also downregulates p27 transcription by phosphorylation-dependent inhibition of the Forkhead family of transcription factors (Medema et al., 2000) . In this sense, we have shown that inhibition of this pathway by LY-294002 increases the p27 levels in PC-3 cells. Thus, it is plausible to think that SHP-1 regulates the levels and subcellular localization of p27 through PI3K-AKT. Our data support this hypothesis. First, we have shown a functional interaction between SHP-1 and PI3K. Second, SHP-1 depletion increases tyrosine phosphorylation of p110 decreasing AKT activity. Several authors have shown that SHP-1 negatively regulates PI3K-AKT signalling by decreasing tyrosine phosphorylation of the p85 subunit (Yu et al., 1998; Cuevas et al., 2001) . However, in this study, we show, for the first time, that SHP-1 may positively regulate PI3K-AKT by modulating tyrosine phosphorylation of the p110 subunit of the PI3K. In this sense, other authors have shown that tyrosine phosphorylation of p110 subunit of inhibits its kinase activity (Nakagawa et al., 2001) .
Very recently, it has been shown that tyrosine phosphorylation of p27 by oncogenic tyrosine kinases such as Src, Lyn or BCR-ABL triggers CDK2-mediated Thr 187 phosphorylation and initiates proteolysis of p27 (Chu et al., 2007; Grimmler et al., 2007) . It is tempting to speculate that SHP-1 may directly dephosphorylate p27, controlling its levels; however, we have not found any interaction between these two proteins. As SHP-1 regulate Src activity (Somani et al., 1997) , this phosphatase might control tyrosine phosphorylation of p27 through Src.
The increase in p27 levels induced by SHP-1 depletion has also been observed in other prostate cancer cells, such as LNCaP and DU145, suggesting that this event is not specific to PC-3 cells but is rather a general event in human prostate carcinogenesis. Our results, however, suggest that p27 upregulation induced by SHP-1 depletion is not directly responsible for cell-cycle arrest. Several recent reports have shown that p27 has cellcycle-independent functions, such as the regulation of cell migration that may be oncogenic under certain circumstances (Besson et al., 2004) . It is tempting to speculate that SHP-1-mediated modulation of the subcellular localization and stability of p27 may lead to the specific loss or gain of some of its functions.
CDK2 mislocalization may be the key event in the SHP-1 knockdown-mediated growth inhibition of PC-3 cells and may be responsible, at least in part, for the maintenance of the anti-proliferative response after p27 loss. Although p27 knockdown decreases p27 accumulation induced by SHP-1 depletion, which frees CDK2 from inhibition, the cytoplasmic localization of CDK2 would impair its activation and also the transition from the G1 to the S phase. The mechanism responsible for CDK2 translocation from the cytoplasm to the nucleus is still poorly understood. CDK2 does not contain a typical 'nuclear localization signal' sequence, so its translocation to the nucleus may depend on its association with partner or carrier proteins that contain this sequence, such as cyclin E (Moore et al., 1999) . Our data strongly suggest, for the first time, that SHP-1 contribute to nuclear translocation of CDK2, as shown by the following two complementary lines of evidence: (i) CDK2 interacts with SHP-1 and (ii) SHP-1 depletion decreases the nuclear localization of CDK2 but does not modify the subcellular localization of cyclin E, implying that the CDK2 nuclear localization is, at least in part, independent of cyclin E and dependent on SHP-1. This phosphatase has a nuclear localization signal at its SHP-1 regulates multiple components of cell-cycle machinery FJ Rodríguez-Ubreva et al C-terminal domain (Craggs and Kellie, 2001 ) and we and other authors have shown that SHP-1 is localized in both subcellular compartments (Ram and Waxman, 1997; Tenev et al., 2000) . Therefore, SHP-1 could substitute for cyclin E and contribute to the shuttling of CDK2 between the cytoplasm and the nucleus. Recently, it has been shown that SHP-1 can associate with CDK2, although in neither case did this interaction directly modify the tyrosine phosphorylation of CDK2 or its kinase activity (Caron et al., 2008; Simoneau et al., 2008) . In the light of our results, we suggest that SHP-1 can directly modify CDK2 activity and its substrate specificity (such as its ability to interact with p27) by regulating the cellular localization of this kinase.
The role of SHP-1 in non-haematopoietic cells has been a matter of controversy. Several reports have described positive effects of SHP-1 on mitogenic signalling (Su et al., 1996; You and Zhao, 1997) whereas other authors, including previous results from our group, claim that SHP-1 mediates the anti-proliferative effect of different peptides (Pages et al., 1999; Zapata et al., 2002) The source of these apparent contradictions may be diverse. First, many earlier studies on the role of SHP-1 in cell signalling have used overexpressing dominant negative mutants, which may have nonspecific effects. Second, catalytically inactive SHP-1 retains its ability as a scaffold protein and the presence of this mutant can modify the catalytic functions but not those that depend on the presence of the protein. Both functions are modified in our experimental system using siRNA against SHP-1. Third, SHP-1 is present in the cytoplasm and nucleus of PC-3 cells. Therefore, the shuttling of SHP-1 between the nucleus and the cytoplasm may constitute a new level of regulation of SHP-1 activity and function. We can speculate that, in a similar way to p27 (Besson et al., 2008) , SHP-1 may have different, even conflicting, functions depending on its subcellular localization, interactions with other proteins and cellular stimuli. The importance of the function and the regulation of SHP-1 in epithelial cells are just beginning to be appreciated, and much work remains to be carried out before we have a full understanding of the regulation of this protein.
Taken together, our results provide new insights into how SHP-1 could modulate the activity of cell-cycle regulators. We have shown a functional interaction between SHP-1 and PI3K-AKT, which may be responsible for the changes in p27 levels and localization induced by SHP-1 depletion. On the other hand, SHP-1 associates with CDK2 and regulates the shuttling of this kinase between the cytoplasm and nucleus, which is necessary for its activation. Our data strongly indicate that that SHP-1 may be required for the correct regulation of events governing cell-cycle progression.
Materials and methods

Cell lines and culture conditions
The prostate cancer cell lines PC-3, LNCaP and DU145 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured in RPMI medium containing antibiotics and 10% foetal bovine serum (Invitrogen, Carlsbad, CA, USA), in the case of PC-3 and DU145, or 7% in the case of LNCaP.
Immunofluorescence Cells were fixed with 4% paraformaldehyde, permeabilized in 0.1% TritonX-100 in PBS for 10 min and stained with primary antibodies indicated followed by Alexa Fluor 633-conjugated anti-rabbit antibody or Alexa Fluor 488-conjugated antimouse antibody (Invitrogen). To perform nuclear staining, cells were incubated with propidium iodide. In some cases, F-actin was stained using Alexa Fluor 488-conjugated phalloidin (Invitrogen). The fluorescent images were acquired using a confocal microscopy Leica TCS-SL.
Transfection of siRNAs
The siRNAs targeting SHP-1 and p27 genes were synthesized by Ambion Inc. (Austin, TX, USA). Transfection were performed using Oligofectamin (Invitrogen) according to the manufacturer's protocol. Target sequences of the siRNAs for SHP-1 knockdown were sense 5 0 -GCA UGA CAC AAC CGA AUA Ctt-3 0 and anti-sense 5 0 -GUA UUC GGU UGU GUC AUG Ctc-3 0 for exon 10 and sense 5 0 -GGU GAC CCA UAU UCG GAU Ctt-3 0 and anti-sense 5 0 -GAU CCG AAU AUG GGU CAC Ctg-3 0 for exon 3. Previously, we compared the effects produced by these siRNAs separately or simultaneously. In all cases, the levels of SHP-1 decreased with a concurrent increase in p27 (Supplementary Figure. S4 ). Therefore, all experiments were made using both siRNAs simultaneously. Target sequences of the siRNAs for p27 knockdown were sense 5 0 -CGU AAA CAG CUC GAA UUA Att-3 0 and anti-sense 5 0 -UUA AUU CGA GCU GUU UAC Gtt-3 0 .
Cell growth assay and DNA synthesis assay Cell growth was measured by counting cells in a Neubauer chamber, after their treatment with 0.05% trypsin and 0.02% EDTA and trypan blue exclusion. For DNA synthesis assay, 72 h after siRNA transfection, cells were pulsed with 1 ml [ 3 H]-thymidine (0.4 mCi/ml) (Amersham, GE Healthcare, Buckinghamshire, UK) for 4 h at 37 1C. After washing three times with PBS, cells were incubated with 1 ml ice-cold 5% TCA for 15 min at 4 1C, washed three times with absolute methanol, air dried and the TCA-precipitable fraction was solubilized in 500 ml of 0.1 M NaOH-1% SDS. Cell-cycle analysis Seventy-two hours after siRNA transfection, cells were washed with PBS and collected by trypsinization. After fixing with cold 75% ethanol for 30 min at 4 1C, cells were treated with 30 mg/ml RNase A for 30 min at 37 1C and then stained with 50 mg/ml propidium iodide. Cell DNA content was determined by flow cytometry using a Becton Dickinson FACScalibur cytometer (BD Biosciences, Bedford, MA, USA). SHP-1 regulates multiple components of cell-cycle machinery FJ Rodríguez-Ubreva et al GST pull-down assay Whole cell lysate was prepared as described earlier (MartinOrozco et al., 2007) and were precleared by incubation with glutathione-sepharose (GE Healthcare); 25 mg of GST-SHP-1 wild type (kindly provided by Dr FD. Bo¨hmer) were bounded to 20 ml of glutathione-sepharose and were then incubated with the precleared PC-3 cell lysate for 1 h at 4 1C. The associated proteins were visualized by SDS-PAGE and inmunoblotting.
Immunoprecipitation and western blot analysis Total cell lysates were obtained and immunoprecipitation and western blot were performed as described earlier (MartinOrozco et al., 2007) . The following antibodies were used anti-phospho-tyrosines, anti-CDK2, anti-CDK6, anti-AKT, anti-cyclin D1, anti-cyclin E, anti-p27, anti-phospho-p27 (S10), anti-p110 and anti-phospho-p27 (T187), obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-phosphopRb (S795), anti-phospho-pRb (S807/811), anti-pRb and antiphospho-AKT (S473) (Cell Signaling Technology Inc., Beverly, MA, USA); anti-phospho-p27 (T157) (R&D Systems Inc., Minneapolis, MN, USA); anti-p85 (Thermo Fisher Scientific Inc., Rockford, IL, USA); anti-PARP and anti-SHP-1 (BD Biosciences).
Transient transfection and luciferase reporter assays
Human p27 promoter containing luciferase reporter construct (p27PF) and control empty vector were gifts from Dr T Sakai Twenty-four hours after siRNA transfection, PC-3 cells were transfected using Lipofectamine Reagent (Invitrogen) according to the manufacturer's recommendations, with a mixture including p27PF or control empty vector. To normalize transfection efficiency Renilla luciferase reporters were included in the transfection. Luciferase activity was measured 48 h post transfection using Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer's instructions.
CDK2 activity assay
Seventy-two hours after siRNA transfection, cells were lysed and equal amounts of proteins were IP with anti-CDK2 antibody at 4 1C overnight. After washing twice with lysis buffer and twice with kinase buffer (Tris-HCl 50 mM pH 7.4, MgCl 2 10 mM, DTT 1 mM, EDTA 1 mM, o-vanadate 1 mM, PMSF 0.1 mM), immunoprecipitates were incubated at 37 1C for 30 min in 10 ml of reaction mixture containing ATP 4 mM, ( 32 gP)-ATP 5 mCi (Amersham), histone-H1 2.5 mg and 6 ml kinase buffer. The reaction mixtures were resolved by SDS-PAGE. CDK2 activity was determined by autoradiography of the dried gels.
Subcellular fractionation
Seventy-two hours after siRNA transfection, cells were lysed using NE-PER nuclear and cytoplasmic extraction reagents (Pierce, Rockford, IL, USA) according to the manufacturer's instructions, to isolate nuclear and cytoplasmic proteins.
Real-time RT-PCR analysis
Total RNA was isolated from PC-3 cells 72 h post transfection by using TRIzol Reagent (Invitrogen) according to the manufacturer's recommendations, and cDNA was produced with the SuperScript II reverse transcription kit (Invitrogen). Real-time RT-PCR was performed using the Universal ProbeLibrary (Roche, Basel, Switzerland) and the following primers: p27 primers: sense, 5 0 -TCAAAGCAAGCTCTTCATA CCC-3 0 , and anti-sense 5 0 -GCACATAAACTTTGGGGAAG G-3 0 ; and 18S primers: sense, 5 0 -TCGGGAGTGGGTAATTTG C-3 0 , anti-sense 5 0 -GGAGAGGGAGCCTGAGAAAC-3 0 . All assays were performed using three separate samples of reverse transcriptase product. The mRNA expression of p27 was normalized using the standard curve method (Larionov et al., 2005) .
Data analysis
Data are presented as mean ± standard error (s.e.) of three independent experiments, which were compared using a paired-sample t-test. A Wilcoxon test for paired samples was used to compare real-time PCR data. In both test, differences are considered statistically significant for values at Po0.05.
